Universitätsklinikum Heidelberg

Treatment landscape and prognosis after treatment with trastuzumab emtansine (2020) Laakmann E, Emons J, Taran FA, Janni W, Uhrig S, Overkamp F, Kolberg HC, et al. Journal article Older age onset of systemic sclerosis - accelerated disease progression in all disease subsets (2020) Moinzadeh P, Kuhr K, Siegert E, Mueller-Ladner U, Riemekasten G, Günther C, Kötter I, et al. Journal article Patch test results with the European baseline series and additions thereof in the ESSCA network, 2015-2018 (2020) Uter W, Bauer A, Belloni Fortina A, Bircher AJ, Brans R, Buhl T, Cooper SM, et al. Journal article Automatic CAD-RADS Scoring using Deep Learning (2020) Denzinger F, Wels M, Breininger K, Gülsün MA, Schöbinger M, Andre F, Buss SJ, et al. Conference contribution, Conference Contribution Early assessment of the risk of later implantloosening using Roentgen Sterophotogrammetric Analysis (RSA). (2020) Seehaus F, Jakubowitz E, Sesselmann S, Kretzer JP, Hurschler C, Sonntag R, Schwarze M Journal article, Review article Defining the clinical, molecular and imaging spectrum of adaptor protein complex 4-associated hereditary spastic paraplegia (2020) Ebrahimi-Fakhari D, Teinert J, Behne R, Wimmer M, D'Amore A, Eberhardt K, Brechmann B, et al. Journal article Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients (2020) Leiter U, Loquai C, Reinhardt L, Rafei-Shamsabadi D, Gutzmer R, Kaehler K, Heinzerling L, et al. Journal article Use of a molecular Registry (PRAEGNANT) for Patient-Selection and Biomarker-Analysis for the SHERBOC Study (2020) Hübner H, Kurbacher C, Kuesters G, Hartkopf AD, Lux MP, Huober J, Volz B, et al. Conference contribution The Work- and Further Training Situation of young Doctors in Further Training in Gynecology - A Standpoint (2020) Lermann J, Knabl J, Neimann J, Schulte K, Proske K, Schott S, Raspe M Conference contribution Progression-free survival and overall survival in patients with advanced her2-positive breast cancer treated with trastuzumab emtansine (T-dm1) after previous treatment with pertuzumab (2020) Michel LL, Hartkopf AD, Fasching P, Kolberg HC, Hadji P, Tesch H, Häberle L, et al. Journal article